Drug
DOVATO
DOVATO is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_4
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
unknown1
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)
Trials by Status
unknown133%
completed133%
not_yet_recruiting133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_4
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
NCT06580873
completedphase_1
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
NCT04827134
unknownphase_3
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
NCT04979468
Clinical Trials (3)
Showing 3 of 3 trials
NCT06580873Phase 4
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
NCT04827134Phase 1
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
NCT04979468Phase 3
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3